aclarubicin and Lymphoma--Non-Hodgkin

Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.

Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunoblastic Lymphadenopathy; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone

Patients with lymphoma who became refractory or resistant to standard chemotherapy including anthracyclines were treated with aclarubicin-combined chemotherapy including VP-16, ifosfamide, and carboquone in a multicenter study. Twenty-one patients were entered in this study, and 18 of them were evaluable. The median age was 52 years old (range 27-74), and there were 17 male and 3 female patients. The vast majority of patients were diagnosed as having diffuse lymphoma, of which 10 cases had large cell type. Surface markers were measured in 8 patients, of whom 4 had T-cell lymphoma. Remission was attained in 3 of 18 patients (17%) with one complete and lasting remission with T-cell lymphoma. In conclusion, the response rate in this study was poor, but this type of combination chemotherapy might be considered in patients with T-cell lymphoma.

Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Recurrence; Remission Induction; T-Lymphocytes; Vinblastine; Vindesine

Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prospective Studies; Random Allocation; Remission Induction; Vincristine

Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary

We present a case of a 59-year-old Japanese man with therapy-related acute myeloblastic leukemia (AML) after the chemotherapy for non-Hodgkin's lymphoma (NHL). Accumulated doses of cyclophosphamide, procarbazine, doxorubicin, mitoxantrone, and etoposide were 18,300 mg, 3000 mg, 580 mg, 100 mg, and 4150 mg, respectively, which had been administered for the treatment of NHL. Myeloblasts in the peripheral blood increased 43 months after the onset of NHL. He was diagnosed as having AML (M2; FAB classification). The karyotype of the bone marrow cells in the present case contained the following abnormalities: t(2;21)(q21;q22), t(8;21)(q22;q22), and add(13)(q34). In the present case, 645 base pairs of chimeric mRNA were detected by reverse transcription-polymerase chain reaction, indicating the presence of AML1/MTG8 rearrangement. Translocation (2;21)(q21;q22) has not been described previously to our knowledge. It is interesting that the breakpoint of 21q22 existed both in t(2;21) and t(8;21). The disrupted AML1 gene resulting from two 21q22 rearrangements may be involved in the pathogenesis of AML in the present case. The clinical importance of therapy-related AML having the 21q22 rearrangement remains to be examined.

Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Polymerase Chain Reaction; Prednisolone; Prednisone; Procarbazine; Proto-Oncogene Proteins; Transcription Factors; Vincristine

From July 1983 to December 1989, 31 previously untreated patients with non-Hodgkin's lymphoma were treated with modified CHOP regimen (cyclophosphamide 300 mg/m2 on day 1, aclacinomycin 40 mg/m2 on day 1, vincristine 0.7 mg/m2 on day 1 and prednisolone 40 mg/m2 on days 1-5). The therapy was repeated at 2-week intervals. The complete response rate was 66.7% for clinical stage (CS) II according to the Ann Arbor criteria, 60.0% for CS III and 33.3% for CS IV, respectively. The 5-year survival rate was 100% for CS II, 36.6% for CS III and 34.6% for CS IV, respectively. Clinical effects of modified CHOP regimen were almost the same as those of other therapies including adriamycin from the standpoint of 5-year survival rate. On the other hand, the myelosuppression accompanying modified CHOP therapy was not severe. Only one patient had a white blood count below 1,000/microliters during 6 courses of the therapy. It is thought that this regimen is useful to enhance the quality of life of patients because of no severe complications such as myelosuppression.

Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Remission Induction; Survival Rate; Vincristine

A total of 40 patients with recurrent non-Hodgkin's lymphoma were treated with ABEP combination chemotherapy (aclarubicin, N4-behenoyl-1-beta-D-arabinofuranosylcytosine, etoposide, and prednisolone). A complete remission (CR) was achieved in 37.5% of the patients and partial remission, in 15.0%. The ABEP regimen proved to be effective in T-cell as well as B-cell lymphoma. It appears that the ABEP regimen may be partially non-cross-resistant with front-line doxorubicin-containing combinations. Survival for 39 months was achieved in 42.0% of the CR responders compared with 6.7% of partial responders (PRs) and nonresponders (NRs) (P less than 0.01). Disease-free survival for 45 months was seen in 66% of the CR patients. The ABEP regimen was effective in the treatment of patients with recurrent or refractory lymphoma, enabling hope for long-term survival in the majority of CR cases.

Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisolone; Remission Induction; Time Factors

Malignant lymphoma is a rare entity in the neoplasms of the female genital tract, and thus a case of malignant lymphoma of the vulva is reported in this paper. On admission, the patient, a 37-year-old, Japanese female, had complained of vulvar swelling and pain that had persisted for one month. Stage IV tumors were noted in the vulva and bladder and a histological diagnosis indicated non-Hodgkin's lymphoma with diffuse, large cell and B cell types, according to the classification of the Lymphoma Study Group. The patient thus was treated with CH* OP therapy, which consisted of Cyclophosphamide, Aclarubicin Vincristine (Oncovin), and Prednine , and given brain irradiation. Unfortunately her condition has rapidly deteriorated during the 5 months since her admission.

Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Prednisolone; Vincristine; Vulvar Neoplasms

Topics: Aclarubicin; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes; Prednisolone; Sex Factors; Vincristine

In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals. Response rates were 15% with treatment 1 and 44% with treatment 2 (overall response rate 34%). Complete remission (CR) was achieved in 6 patients who had previously failed to respond to adriamycin (ADM). Toxicity was more frequent and more severe in those patients given more than 150 mg/m2 ACM per course. The main side effects were oropharyngeal mucositis and diarrhea. Three patients exhibited T wave inversion and one had an episode of auricular flutter. In a separate trial in 16 patients with AML we used cyclic chemotherapy combining ACM (20 mg/m2/d) and ARA-C (200 mg/m2/d) for seven consecutive days. Complete remission rate was 50%. Severe ventricular rhythm disorders were seen in two patients. In a phase I-II study, 19 patients with acute lymphoid leukemia (ALL) and 8 patients with non-Hodgkin lymphoma (NHL) were given ACM alone according to the regimen designated treatment 1 described above. Response rates were 11% (2/19) in ALL and 25% (2/8) in NHL. A review of the literature is presented in the discussion of the original trials reported herein.

Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes

Activities of marker enzymes for various cell components were studied with extracts of adriamycin-, aclacinomycin A- and bleomycin-resistant cells and with partially purified plasma membrane fraction of aclacinomycin A-resistant cells, in comparison with those of the parental cells. Alkaline phosphodiesterase and Na+-K+-ATPase activities were observed to alter in the drug-resistant sublines, but other enzymes showed similar activities in the resistant cells to those in the parental cells. Alkaline phosphodiesterase activities in all the resistant sublines were higher than that in the parental cells. Na+K+-ATPase activities of anthracycline-resistant sublines were lower and that in bleomycin-resistant cell line was higher than that of the parental cells. The adriamycin-resistant cells exhibited the same level of alkaline phosphodiesterase activity with the aclacinomycin A-resistant cells: Vmax was the same with, and the affinity was twice stronger than the parental cells. The bleomycin-resistant cells showed ca. 30% Vmax in comparison with the sensitive cells, and 17 fold higher affinity than the parental cells. The current results, concerning changes of membrane-associated enzymes in drug-resistant sublines of L5178Y cells, support the assumption that the resistance is due to alteration of plasma membrane transport systems.

Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Line; Cell Membrane; Doxorubicin; Drug Resistance; Lymphoma, Non-Hodgkin; Mice; Naphthacenes; Phosphoric Diester Hydrolases; Sarcoma, Experimental; Sodium-Potassium-Exchanging ATPase

Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Drug Evaluation; Female; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes

New anthracycline antibiotics have been isolated from the culture of Streptomyces galilaeus MA144-M1. Among 14 anthracycline compounds, aclacinomycin-A showed the strongest activity in inhibiting leukemia L-1210 and had lower toxicity than others. Antitumor activity of aclacinomycin-A against leukemia L-1210 and P-388, solid sarcoma-180, and lymphosarcoma 6C3HED was examined in comparison with adriamycin and daunomycin. Aclacinomycin-A showed the same degree of activity against leukemia L-1210 and P-388, when administered intraperitoneally, as daunomycin and somewhat less than adriamycin. In oral administration, aclacinomycin-A also exhibited a significant activity on leukemia L-1210. The degree of inhibition of the growth of sarcoma-180 and 6C3HED lymphosarcoma transplanted subcutaneously by aclacinomycin-A was almost the same as that of adriamycin and daunomycin, although the optimal dose was about twice more than adriamycin. Acute cardiotoxicity of aclacinomycin-A by a test using hamsters was more than 10 times lower than that of adriamycin.

Topics: Aclarubicin; Animals; Anthraquinones; Antibiotics, Antineoplastic; Cricetinae; Daunorubicin; Doxorubicin; Electrocardiography; Glycosides; Heart; Leukemia L1210; Leukemia, Experimental; Lymphoma, Non-Hodgkin; Male; Mesocricetus; Mice; Mice, Inbred Strains; Sarcoma 180; Sarcoma, Experimental; Streptomyces